Novartis’ Martin Seidel Joins IFM Therapeutics as V.P. of R&D

Xconomy Boston — 

Martin Seidel is joining IFM Therapeutics to become the Boston biotech’s executive vice president of research and development. Seidel comes to IFM from Novartis (NYSE: NVS), where he was most recently global head of strategic alliances for the Novartis Institutes for Biomedical Research (NBIR). Before that, he was head of NBIR’s Genomics Institute of the Novartis Research Foundation. IFM is developing drugs that target the innate immune system to treat cancer, and inflammatory and autoimmune diseases.